Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
BRIEF: China Traditional Chinese Medicine’s profit tumbles in 2024
China Traditional Chinese Medicine Holdings Co. Ltd. (0570.HK) on Wednesday warned that it expects to report its profit for all of 2024 fell by 90% to 100%, while its adjusted…
Saint Bella births Hong Kong IPO, in race to nurture a postpartum empire
The company is feeding off growing Chinese demand for postpartum care, but could face headwinds from a slowing economy and plunging birthrates Key Takeaways: Saint Bella has filed to list…
BRIEF: Ping An Healthcare controlling shareholder makes share offer, says no plans for privatization
Online healthcare platform Ping An Healthcare (1833.HK) announced on Tuesday evening that its controlling shareholder, Ping An Insurance (2318.HK; 601318.SH), has offered to buy all of the company’s shares under…
BRIEF: Concord Healthcare ties with Mayo Clinic to improve management
Medical services provider Concord Healthcare Group Co. Ltd. (2453.HK) said Thursday it has entered into an agreement for Mayo Foundation, operator of the Mayo Clinic, to provide it with consulting…
INVESTOR VIEW: AIX is an underrated star in the AI insurance and health sectors
The company’s recent combination with BGM Group through an acquisition puts it in strong position to benefit from future integration of AI into the insurance business By Rucha Gupda…
BRIEF: Xunfei Healthcare to raise $75 million in Hong Kong IPO
Xunfei Healthcare Technology Co. Ltd. (2506.HK), the healthcare arm of artificial intelligence company iFlytek (002230.SZ), said it expects to raise about HK$580 million ($75 million) in its Hong Kong IPO. Xunfei…
Recent Articles
BRIEF: Ping An Healthcare controlling shareholder makes share offer, says no plans for privatization
1833.HK
2318.HK
601318.SHG
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
- Shanghai Able’s renewed IPO plan hobbled by weak appetite for new tech listings
